Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Will this be halted until june 15th?

Bullboard Posts

Comment by MyKnighton May 19, 2020 9:59am

49 Views

Post# 31045420

RE:RE:Will this be halted until june 15th?

THis mean that their's more news coming....

RE:Will this be halted until june 15th?

BTRU $0.075 premarket $0.10 plus
News friday

yes halted June 1st

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading

BMO evolves InvestorLine with enhanced tools for options trading

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity

Visionstate set to leverage success in the U.S. market

Visionstate set to leverage success in the U.S. market

Debt-free cannabis company set for next stage of growth

Debt-free cannabis company set for next stage of growth